CAM
ELVN icon

Cormorant Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Cormorant Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,000
Closed -$4.09M – 39
2025
Q3 		$4.09M Hold
200,000
– – 0.28% 35
2025
Q2 		$4.01M Sell
200,000
-50,000
-20% -$947K 0.3% 38
2025
Q1 		$4.92M Hold
250,000
– – 0.37% 39
2024
Q4 		$5.63M Buy
+250,000
New +$6.48M 0.31% 36
2023
Q4 		– Sell
-1,216,712
Closed -$16.6M – 51
2023
Q3 		$16.6M Sell
1,216,712
-719,421
-37% -$12.1M 0.97% 26
2023
Q2 		$39.5M Hold
1,936,133
– – 2.21% 10
2023
Q1 		$42.4M Buy
+1,936,133
New +$39.4M 2.79% 9

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return